Revolution Medicines Presents Strong Phase 2 KRAS Inhibitor Data for Pancreatic Cancer at AACR 2026

Revolution Medicines presented additional strong Phase 2 clinical data on its KRAS inhibitor (RMC-6236) for pancreatic cancer at the American Association for Cancer Research (AACR) 2026 annual meeting. The results reinforced earlier promising signals in a cancer type historically resistant to targeted therapy. The company also offered a glimpse at a potential next-generation compound class designed to move beyond current KRAS inhibitor limitations, signaling a new frontier in RAS-targeted oncology.